Meet our volunteers: Cindy Peacock
“Being part of something and feeling that you are not alone,” are just two of the positive benefits Cindy Peacock says she experiences as a volunteer with Retina UK.
Search
Search results
ProQR announces suspension of LCA10 and USH2A clinical trials
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.
Your donations make progress possible
Your generous support allows Retina UK to fund the work of leading scientists who are increasing understanding of inherited sight loss and moving us closer to treatments.
Research update – ProQR
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
ReNeuron trial FAQs
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
e-Newsletter September 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK.
e-Newsletter May 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Walking into Wellness: Uniting Movement and Mental Health this May!
Did you know May is National Walking Month? As part of Mental Health Awareness Week, we're exploring the power of movement.
Webinar: Walking into Wellness: Uniting Movement and Mental Health this May!
Did you know May is National Walking Month? As part of Mental Health Awareness Week, we're exploring the power of movement.
A new approach to treating inherited sight loss
A new approach to treating inherited sight loss